About this study
This study looks at a new treatment for children and young adults with solid tumors that have been difficult to treat (refractory) or have come back after treatment (relapsed).
The new treatment is called CAR T-cell therapy. CAR T-cell therapy is a type of immunotherapy. It uses infection-fighting cells from the body’s immune system to target cancer cells. The infection-fighting cells used in this study are called T cells. Scientists insert a protein called a chimeric antigen receptor (CAR) into T cells to give them the ability to kill cancer cells. The CAR T-cell target in this study is a particle called B7-H3. B7-H3 is found on many different types of pediatric solid tumors.
Eligibility overview
Inclusion criteria
- Up to 21 years old
- Relapsed or refractory B7-H3-positive solid tumor
- Measurable disease (evaluable disease for patients with neuroblastoma)
- Adequate heart, lung, liver, kidney and bone marrow function
Exclusion criteria
- History of HIV infection
- Therapy that will interfere with B7-H3-CAR T-cell function within 14 days prior to CAR T cell infusion
- Rapidly progressing disease
- Known underlying medical condition for which participation would not be in the best interest of the participant or that could prevent, limit or confound protocol assessments